Table 3 Associations between the baseline PFAS concentrations and the change in eGFR over time following adjustment for age (time), BMI, smoking, HDL- and LDL-cholesterol, triglycerides, glucose, and statin use.
From: Longitudinal and cross-sectional analysis of perfluoroalkyl substances and kidney function
PFAS | Main effect (β), 95% CI | Interaction effect (β), 95% CI |
|---|---|---|
PFHpA | −0.842 (−1.869, 0.184) | 0.357 (−1.983, 2.699) |
PFHxS | 1.128 (0.159, 2.096) | 0.029 (−1.979, 2.038) |
PFOA | 1.702 (0.326, 3.078) | 0.446 (−2.628, 3.521) |
PFNA | 3.593 (2.274, 4.912) | −1.891 (−4.818, 1.037) |
PFDA | 3.586 (1.656, 5.516) | −2.125 (−6.100, 1.852) |
PFOSA | −3.722 (−4.805, −2.640) | 5.805 (3.334, 8.277) |
PFUnDA | 4.377 (2.586, 6.169) | −3.090 (−6.912, 0.732) |
L-PFOS | 1.143 (0.278, 2.008) | 0.625 (−1.377, 2.627) |
